Susquehanna International Group’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-91,976
| Closed | -$61K | – | 10967 |
|
|
2017
Q4 | $61K | Buy |
+91,976
| New | +$46.4K | ﹤0.01% | 8861 |
|
|
2017
Q1 | – | Sell |
-71,827
| Closed | -$89.8K | – | 10986 |
|
|
2016
Q4 | $95K | Buy |
+71,827
| New | +$125K | ﹤0.01% | 9112 |
|
|
2016
Q1 | – | Sell |
-25,423
| Closed | -$24.8K | – | 10514 |
|
|
2015
Q4 | $31K | Sell |
25,423
-13,452
| -35% | -$43.2K | ﹤0.01% | 9180 |
|
|
2015
Q3 | $289K | Sell |
38,875
-96,787
| -71% | -$740K | ﹤0.01% | 8100 |
|
|
2015
Q2 | $970K | Buy |
135,662
+19,089
| +16% | +$149K | ﹤0.01% | 6283 |
|
|
2015
Q1 | $1M | Buy |
116,573
+53,977
| +86% | +$483K | ﹤0.01% | 5767 |
|
|
2014
Q4 | $624K | Sell |
62,596
-57,551
| -48% | -$491K | ﹤0.01% | 6817 |
|
|
2014
Q3 | $1.19M | Buy |
120,147
+74,238
| +162% | +$1.1M | ﹤0.01% | 5610 |
|
|
2014
Q2 | $794K | Sell |
45,909
-82,862
| -64% | -$1.35M | ﹤0.01% | 6546 |
|
|
2014
Q1 | $2.28M | Buy |
+128,771
| New | +$2.49M | ﹤0.01% | 4107 |
|
|
2013
Q4 | – | Sell |
-259,335
| Closed | -$4.9M | – | 9874 |
|
|
2013
Q3 | $6.95M | Sell |
259,335
-113,075
| -30% | -$2.42M | ﹤0.01% | 2285 |
|
|
2013
Q2 | $6.87M | Buy |
+372,410
| New | +$6.58M | ﹤0.01% | 2215 |
|
Susquehanna International Group's RPRX Position: Q1 2018 in Review
Susquehanna International Group sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 91,976 shares — an estimated $61K sold.
Susquehanna International Group first reported a position in RPRX in Q2 2013 and held it in 12 quarters. The position peaked at $6.95M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Susquehanna International Group reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Susquehanna International Group sold 91,976 Repros Therapeutics Inc. shares in Q1 2018, an estimated $61K.
- Susquehanna International Group first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 12 quarters.
- Susquehanna International Group's Repros Therapeutics Inc. position peaked at $6.95M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Susquehanna International Group's 13F filing for Q1 2018, filed 15 May 2018.